ValiRX
ValiRx PLC accelerates the development of innovative medicines that enhance patient experience.
Financials
Estimates*
| GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | <1m | - | <1m | - | - | - |
| EBITDA | (4.0m) | (2.9m) | (3.7m) | (2.5m) | (1.4m) | (1.4m) | (2.4m) |
| % EBITDA margin | - | (3309 %) | - | (1717 %) | - | - | - |
| Profit | (5.1m) | (3.1m) | (4.4m) | (2.4m) | (1.5m) | (1.5m) | (2.4m) |
| % profit margin | - | (3534 %) | - | (1656 %) | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | £238k | Grant | |
£240k | Grant | ||
| N/A | £800k | Post IPO Equity | |
* | N/A | £1.8m | Post IPO Equity |
| Total Funding | €573k | ||
Recent News about ValiRX
EditInvestments by ValiRX
Edit
ACQUISITION by ValiRX Jul 2008